rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    IMMX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
      Nov 12Yahoo FinanceIMMX
      Immix Biopharma to present AL amyloidosis data at ASH meeting
      Nov 4Investing.comIMMX
      Immix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026
      Nov 4Yahoo FinanceIMMX
      Immix Biopharma (IMMX) Stock Sees Modest Fair Value Lift After Split Analyst Revisions
      Oct 21Yahoo FinanceIMMX
      Morgan Stanley initiates Immix Biopharma stock with overweight rating
      Oct 20Investing.comIMMX
      Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
      Oct 5Yahoo FinanceIMMX
      Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study

      Immix Biopharma (NASDAQ:IMMX) reported updated clinical data for NXC-201, its investigational CAR T-cell therapy for relapsed or refractory light-chain (AL) amyloidosis, and outlined plans for a biologics license application, a frontline study and a targeted commercial launch strategy. AL amyloidos

      Oct 5Yahoo FinanceIMMX
      Immix Biopharma Prices $125 Million Equity Offering

      Detailed price information for Immix Biopharma Inc (IMMX-Q) from The Globe and Mail including charting and trades.

      Oct 1The Globe and MailIMMX
      Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC), Immix Biopharma (IMMX) and Surgery Partners (SGRY)

      Detailed price information for Surgery Partners CS (SGRY-Q) from The Globe and Mail including charting and trades.

      Oct 1The Globe and MailIMMXRNACSGRY
      Immix Biopharma closes $117.1m stock offering
      Sep 30Investing.comIMMX
      Immix Biopharma Closes $125 Million Stock Offering

      Immix Biopharma (IMMX) closed its previously announced underwritten offering of 11.4 million common

      Sep 30Yahoo FinanceIMMX
      Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

      – Financing includes leading U.S. biotechnology institutional investors and mutual funds –LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The net proceeds to Immix from the offering, after ded

      Sep 30Yahoo FinanceIMMX
      Exclusive BAC Article: Immix Biopharma; Two Positive Interim Updates NXC-201 For R/R AL Amyloidosis, Final Data Plus BLA Filing Mid-2027 And Catalysts (NASDAQ:IMMX)

      I believe that a good speculative biotech to go over for the Exclusive BAC Subscribers Article would be Immix Biopharma (IMMX).

      Sep 30Seeking AlphaIMMX
      Citizens reiterates Immix Biopharma stock rating on trial data
      Sep 30Investing.comIMMX
      Immix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 Trial
      Sep 29Yahoo FinanceIMMX
      Immix posts new trial data for AL amyloidosis drug (IMMX)
      Sep 29Seeking AlphaIMMX
      Immix Biopharma reports 89% complete response rate in trial
      Sep 29Investing.comIMMX
      Immix Biopharma prices $125M stock offering at $11 per share
      Sep 29Investing.comIMMX
      BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock
      Sep 29Yahoo FinanceIMMX
      Immix Biopharma Prices $125 Million Stock Offering
      Sep 29Yahoo FinanceIMMX
      Mizuho raises Immix Biopharma stock price target to $26 on expansion
      Sep 15Investing.comIMMX
      Mizuho Raises Price Target on Immix Biopharma to $26 From $15, Keeps Outperform Rating
      Sep 15Yahoo FinanceIMMX
      Immix Biopharma at Morgan Stanley conference: CAR T push gains pace
      Sep 14Investing.comIMMXMS
      AITX's RAD Goes Live on Immix with ROSA & RIO

      ROSA and the RIO Platform Integration with Immix Now Available for Use, with the Nation's Largest Guarding and Monitoring Companies EngagedDetroit, Michigan--(Newsfile Corp. - September 14, 2026) - Artificial Intelligence Technology Solutions, Inc. (OTCID: AITX), today announced that the integration of its subsidiary, Robotic Assistance Devices, Inc. (RAD), with the Immix® platform is now available to Immix users, supporting RAD's ROSA™ and RIO™ platforms. The move to full release follows the...

      Sep 14Yahoo FinanceIMMX
      Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and Immix Biopharma (IMMX)

      Detailed price information for Xenon Pharmaceuticals Inc (XENE-Q) from The Globe and Mail including charting and trades.

      Sep 11The Globe and MailIMMX

      This is the newest page. Registered accounts read further back.